International Assets Investment Management LLC Takes Position in Grifols, S.A. (NASDAQ:GRFS)

International Assets Investment Management LLC acquired a new position in Grifols, S.A. (NASDAQ:GRFS) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 19,163 shares of the biotechnology company’s stock, valued at approximately $1,700,000.

Other large investors have also recently added to or reduced their stakes in the company. Team Hewins LLC grew its stake in shares of Grifols by 11.8% in the first quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 4,324 shares in the last quarter. Sei Investments Co. grew its position in Grifols by 5.3% in the 1st quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock valued at $14,091,000 after buying an additional 107,000 shares in the last quarter. Anthracite Investment Company Inc. acquired a new position in Grifols during the 1st quarter valued at about $1,970,000. Capital Group Investment Management PTE. LTD. raised its position in shares of Grifols by 11.8% during the 1st quarter. Capital Group Investment Management PTE. LTD. now owns 81,955 shares of the biotechnology company’s stock worth $547,000 after buying an additional 8,660 shares in the last quarter. Finally, Capital International Ltd. CA lifted its stake in shares of Grifols by 4.9% in the 1st quarter. Capital International Ltd. CA now owns 408,110 shares of the biotechnology company’s stock worth $2,726,000 after acquiring an additional 19,048 shares during the period.

Grifols Stock Performance

Shares of Grifols stock opened at $8.84 on Monday. The business has a fifty day simple moving average of $8.82 and a 200-day simple moving average of $7.80. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.